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Genomic risk information for potentially actionable complex diseases and pharmacogenomics 
communicated through genomic counseling may motivate physicians and patients to take preventive 
actions. The Ohio State University-Coriell Personalized Medicine Collaborative is a randomized trial to 
measure the effects of in-person genomic counseling on chronic disease patients provided with multiplex 
results. Nine personalized genomic risk reports were provided to patients through a web portal, and to 
physicians via electronic medical record (EMR). Active arm participants (98, 39% female) received 
genomic counseling within one month of report viewing; control arm subjects (101, 54% female) could 
access counseling 3-months post-report viewing. We examined whether genomic counseling affected 
documentation of physician-patient communication by reviewing the first clinical note following the 
patient’s genomic counseling visit or report upload to the EMR. Multivariable logistic regression 
modeling estimated the independent effect of genomic counseling on physician-patient communication, 
as Intention to Treat (ITT) and Per Protocol (PP), adjusted for physician educational intervention. 
Counselees in the active arm had more physician-patient communications than control subjects (ITT, OR: 
3.76 (95% CI: 1.38 – 10.22, P<0.0094); PP, OR: 5.53 (95% CI: 2.20 – 13.90, P=0.0017). In conclusion, 
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genomic counseling appreciably affected physician-patient communication following receipt of 
potentially actionable genomic risk information. 
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Genomic medicine is an emerging medical discipline that involves using a patient’s family history, 
genetic, protein, metabolic and other biological marker profiles in the clinical setting. Knowledge of a 
patient’s genomic profile could help identify and manage health risks, aid in the diagnosis of existing 
disease, determine what interventions (e.g. pharmacologic, surveillance) will have the greatest benefit, 
and improve patient-centered health outcomes. To reach this goal, a number of complex issues must be 
resolved, including optimizing patient genomic testing result delivery, preparation of the physician 
workforce, and evidence-based research to systematically evaluate the translation of genomics into 
clinical care (1-7). 
To date, there have been relatively few studies examining the potential effects of delivery of 
actionable genomic risk information on physician-patient communication (8, 9), or how genomic 
counseling might affect this process. Physician-patient communication, including patient activation, is 
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associated with greater adherence to health care provider recommendations and greater patient 
satisfaction (10, 11). However, even when actionable genomic risk information is available, participants 
often keep the results to themselves. Kaufman et al., surveying participants of direct to consumer 
genomic services, found that only 28% discussed actionable test results with a health care provider, most 
often a primary care physician, and seldom with a genetic counselor (12). Similar physician involvement 
was seen by Bloss et al. (13), and more recently, by van der Wouden et al. (14) (26.5% and 27%, 
respectively). Bloss et al. also found that 1) speaking with a physician or genetic counselor about results 
was not associated with a change in anxiety level, and 2) those who discussed results had a higher 
completion rate of recommended health screening tests (e.g. diabetes) at long term follow-up (9). 
We sought to determine whether in-person genomic counseling offered to patients receiving 
potentially actionable genomic risk information as part of a randomized trial affected patient 
communication with their physician team. Specifically, we examined whether genomic counseling 
affected documentation of physician-patient communication about genomic test results, determined by 
review of the first clinic note following test report upload to the electronic medical record, or after the 
patient met with a genomic counselor.  
 
METHODS 
The Ohio State University-Coriell Personalized Medicine Collaborative (OSU-CPMC) parent study is a 
randomized clinical trial of in-person genomic counseling (GC) for patients with chronic disease (heart 
failure, hypertension) receiving potentially actionable results in an academic medical center setting 
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(Figure 1a).  The primary study aim was to determine whether genomic counseling impacts risk perception 
and genomic test result comprehension (15).  As part of the parent study, we recruited physicians taking 
care of OSU-CPMC patients into a pilot study to explore test result utilization and physician-patient 
communication regarding results (Figure 1b) (15). The study was approved by the institutional review 
boards at Ohio State and the Coriell Institute for Medical Research. 
  
Physician participants 
Patients were enrolled with the assistance of Cardiovascular Medicine, Internal Medicine, and Family 
Medicine physicians. Physician leaders, one each from Cardiovascular Medicine and Internal Medicine, 
arranged informational group meetings among their physician colleagues. For these two groups, 
physician participation included attending a one-hour in-person educational module on the study 
randomization component, genetics/genomics/pharmacogenomics, single nucleotide polymorphisms 
and associated relative risks, test report composition, case examples and the process of genomic 
counseling. In all, we had twenty physicians (response rate, 57%; 12/27 Internal Medicine; 8/8 
Cardiovascular Medicine) who consented to participate and worked with investigators to recruit patients.  
As study design required a sufficient number of physicians to be involved in order to accrue an adequate 
number of patients, leadership in the Department of Family Medicine were approached. However, this 
group was not interested in having their physician teams participate in the one-hour in-person 
educational module given work time constraints. Thus, a one-hour educational webinar accredited by 
Ohio State Wexner Medical Center for a maximum of 1.5 AMA PRA Category 1 Continuing Medical 
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Education Credit(s)™ was made available. In total, 10 Family Medicine physicians participated in 
recruiting patients to study; however, none chose to view the webinar.  
All study physicians were informed that each patient participant was provided access to 9 
personalized CPMC risk reports (coronary artery disease, type 2 diabetes, hemochromatosis, melanoma, 
prostate cancer, age related macular degeneration, type 1 diabetes and lupus as well as impact of the 
CYP2C19 gene on clopidogrel metabolism) through a private web portal. These eight conditions were 
chosen given the relative high frequency of the genetic variant used to assess risk; varied effect size of 
each variant on risk; and that each condition is potentially actionable via lifestyle modification or medical 
intervention (Table 1) (17). The reports present personalized risk information as relative risk for each of 
the 8 health conditions, based on genetic variant, family history and health behavior risk factors 
individually, in both graphical and numeric format (Supplemental Figure 1). To ensure readability, the 
report design was informed by multiple rounds of pilot testing conducted by allowing individuals with no 
scientific background to review report drafts and provide feedback.      
Physicians were made aware that their patient’s test reports would be made available following 
patient completion of required baseline surveys, genomic testing completion by the Coriell CLIA certified 
genotyping lab, report transfer from Coriell to Ohio State, and direct uploading to an EPIC® electronic 
medical record (EMR).  The CPMC reports were accessible by the study physician or any health care team 
member through hyperlinks to the report content via the EPIC®/Labs tab.  Likewise, physicians were 
made aware that if a patient participant was seen for genomic counseling, the summary letter would be 
made available in the EPIC® EMR as a research encounter. Per study design, there was no active 
notification of physicians for test report upload, or summary letter upload to the EMR. 





252 patient participants were enrolled by study physicians with assistance of study recruiters over a two 
year period; 4 additional patients were recruited via Media/Research Match with physician involvement. 
Patient participants were administered a one-hour educational presentation including access to the 
CPMC web portal, background information on DNA, genes, and single nucleotide polymorphisms, CPMC 
test report composition, relative risk, the randomization component, and how they would be contacted 
regarding the availability of free GC. DNA samples and consent documentation were sent to Coriell, and 
unique CPMC web portal accounts were created for each patient participant. 53 patients were 
subsequently removed from study (51 failed to complete all required parent study questionnaires; 2 due 
to unsuccessful genotyping). Thus, of the original 252 study participants, 199 patient participants 
comprised the study population. These individuals were randomized to either the active or control arm, 
with each arm receiving email notification of the availability of the initial batch of nine CPMC test 
reports. Active arm participants were called to schedule a GC appointment within four weeks of online 
viewing of at least one test report. Control arm participants were notified by email that they could 
request in-person GC after a 3-month randomization period, and after the viewing of at least one test 
report. Contact information to schedule the GC appointment for control arm participants was provided 
in the email. Study participants in both the active and control arms, who received GC, comprised the 
“Received GC” group.  
This article is protected by copyright. All rights reserved.
9 
 
The in-person GC session, provided by one of two available licensed genomic counselors, 
focused on individualized risk assessment for all nine personalized CPMC risk reports. During each 
session, the genomic counselor reviewed and expanded the patient’s family history to obtain at least a 3-
generation pedigree, and reviewed the patient’s medical and social history, environmental risk 
information, and current health promotion and screening practices (15). Sessions included active 
discussion of the major risk factors for a given disease, specific actions to prevent or lower disease risk, 
and recommendations for the patient participant to speak to their physician team regarding the 
recommended actions. A multi-page risk summary letter, developed by the investigation team, provided 
focused interpretation for each of the nine personalized CPMC risk reports, as well as recommendations 
based on the patient’s medical and family histories.  The GC summary letter was mailed to the patient, 
and also uploaded directly to the EMR. 
 
Procedures 
Each patient’s EMR was reviewed from the date the genomic reports were uploaded (e.g. November 8, 
2011 for the initial round of patients accrued to study), until the study was closed for analysis on August 
22, 2014. Specifically, any documented interaction/note (e.g. office visit; phone call; Table 2a) that 
occurred between the patient participant, the study physician, or any member of the health care team 
was manually reviewed by KS for the following study related search terms: Coriell, CPMC, genetic, 
genomic, genomic counseling, pharmacogenomic and variant. All relevant physician-patient 
communications (e.g. discussion of test results) related to these search terms, either by the study 
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physician, or any medical provider were recorded. The number of times the patient participant was seen 
by the study physician during the time frame of chart review, with documentation of the first clinic 
interaction after upload of CPMC test reports, was recorded. If a patient participant was seen for GC, the 
number of times the patient was subsequently seen by the study physician, and date of the first clinic 
interaction post-GC was recorded. A second investigator, AS, subsequently performed manual review of 
the EMR with use of the 7 study related search terms for concordance. Both investigators (KS, AS) agreed 
upon a subset of physician-patient communications. Following this initial round of manual chart review, 
investigators had opportunity to use a new EPIC® informatics-based text search. As such, a second round 
of record review was performed by KS utilizing the same list of 7 key search terms, and modifications 
were made to the original spreadsheet. Again, all recorded physician-patient communications were 
verified using the EPIC® search function by a second investigator (AS). Both reviewers agreed on the final 
subset of physician-patient communications, as well as the placement of each communication into 
specific categories. Examples of physician-patient communications are found in Table 2b. Review of the 
EMR took between 15 minutes and 3 hours per patient participant to complete.   
 
Outcome of Interest 
The primary study outcome of interest was defined as any physician-patient communication about the 
test results on the patient’s first interaction with their physician after EMR results were uploaded for 
control arm participants or after GC for active arm participants.  
 




Descriptive statistics for socio-demographic and clinical variables were generated and compared 
between study arms. Both the “Intention-To-Treat (ITT)” analysis and the “Per-Protocol (PP)” analysis 
were performed for a robust interpretation of study results (16). As there were 30 subjects who did not 
return for a physician visit after the EMR report upload or after GC, comparison on age, gender, race, 
education, insurance, disease groups, and number of elevated genetic variant risks (RR>1.2) between 
these 30 subjects with the rest of the sample population was performed to show no significant 
difference.  Outcomes were analyzed on the assumption that physician communication could not be 
generated for those patients who did not come back for a clinical visit or have any documented physician 
encounter (null imputation). Multivariable logistic regression models were used to estimate the effects 
of GC and physician education intervention on any recorded physician-patient communication regarding 
genomic testing results. In order to capture the within-physician clustering arising from physicians who 
recruited more than one patient, these models were estimated using generalized estimating equations 
with an independent working correlation structure and robust standard errors. Possible confounder 
effects, including patient’s age, gender, education, and disease group were also examined. Due to the 
sample size limitation, these effects were examined in individual models. A two-sided significance level 
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Table 3a depicts basic characteristics and socio-demographic information for each arm (ITT analysis; 98 
active; 101 control). Table 3b describes each arm per protocol (i.e. had GC vs. did not have GC). There 
were no significant differences in demographics between the study groups based on randomization or 
receiving GC except more males were randomized into active arm. Of 199 study participants, 137 (68.8%) 
had an associate’s degree or higher; 180 (90.4%) were white. There were more male participants, 107 
(53.8%), than female; 25 (12.5%) worked in a health care related occupation (e.g. nursing). Mean age 
was 58.1 years (range from 24 to 94). All 199 study participants received email notice of the availability 
of the initial batch of 9 test reports in their web portal, of which 183 participants viewed at least one 
CPMC report. There were 40 subjects with 1 elevated genetic variant risk variable; 68 subjects with 2 
elevated genetic risk variables; and 87 subjects with 3+ elevated genetic risk variables. In all, 33 (16.6%) 
participants had intermediate and 3 poor metabolizer response to Clopidogrel. The average number of 
participants’ visits to physician after initial results uploaded to EMR was 2.8 (median: 2; range 0-9). Of 80 
active arm participants scheduled for in-person GC, 76 (95%) were seen. In the control arm, 15/101 
contacted investigators after the randomization period and received in-person GC three or more months 
after viewing at least one result. Thus, the Received GC group comprised 91 individuals. Comparisons on 
age, gender, race, insurance, education, disease groups, and number of elevated genetic risk variants did 
not show significant differences between the 22 subjects in the active arm who did not receive GC and 
the rest of the subjects in the active arm who did receive GC. No significant difference was found in the 
control arm between those who received GC and those did not. Participants in the GC arm were 
followed-up for an average of 222 days (median: 154; range: 36-1010), which was similar to an average 
of 175 days follow-up for participants in the control arm (median: 101; range: 30-739). 




Physician-patient result communication on first clinic interaction (ITT analysis) 
Using an ITT framework, there were a total of 17 physician-patient communications regarding genomic 
testing results (e.g. specialty referral; discussion of test results; Table 2b) on the patient’s first clinic 
interaction (13, active arm; 4, control arm). Median time to first clinic interaction was 198.5 days (range: 
44-651) in the active arm and 78.5 days (range: 1-644) in the control arm.  Active arm participants 
receiving GC as randomized was a significant predictor of physician-patient communication regarding 
testing results on the first clinic interaction (Table 4a). The odds of having this communication exchange 
on the patient’s first interaction after EMR report upload or after GC for active arm participants was 3.76 
times higher than for control subjects (95% CI: 1.38 – 10.22, P<0.0094). Neither physician educational 
intervention nor its interaction with the GC arm was a significant predictor. The ORs were not 
significantly modified after adjusting for patient’s age, gender, education, disease group, or number of 
elevated genetic variant risks in separate modeling (Table 4b). However, the odds of having 
communication exchange on the patient’s first interaction for GC arm as randomized was greatly 
increased after adjusting for the number of days between the EMR results uploaded and the first clinic 
interaction (OR: 6.16, 95% CI: 2.07 – 18.37, P=0.003). The association between physician-patient result 
communication with age, gender, education, disease number of elevated risks, or the number of days 
between the EMR results uploaded and the first clinic interaction was not significant in any of the 
separate models. 
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Physician-patient result communication on first clinic interaction (PP analysis) 
Using a “per protocol” framework, there were a total of 20 physician-patient communications regarding 
genomic testing results noted on the first clinic interaction after receiving GC (16, active arm; 4 control 
arm). Median time to first clinic interaction was 205 days (range: 44-833) for patients who received GC 
and 80 days (range: 1-534) for patients who did not receive GC.  The distribution of physician-patient 
communications is shown in Figure 1. The odds for participants that received GC to engage in physician-
patient communication regarding genomic testing results at the patient’s first clinic interaction after GC 
were 5.53 (95% CI: 2.20 – 13.90, P=0.0017) times higher than for patients who did not receive GC (Table 
5a). Neither physician educational intervention nor its interaction with actual GC group was a significant 
predictor. The ORs were not significantly modified after adjusting for patient’s age, gender, education, 
disease group, the number of elevated genetic variant risks, or the number of days between EMR results 
uploaded and the first clinic interaction in separate models (Table 5b).  The association between 
physician-patient result communication with age, gender, education, disease group, number of elevated 
risks, or the number of days between EMR results uploaded and the first clinic interaction was not 
significant in any of the separate models. 
 
Physician-patient result communication for any interaction during the follow-up period 
Secondary analyses were performed with any note documenting physician-patient communication about 
the study results throughout the follow-up period. Most of the physician-patient communication 
occurred on the first interaction, with only 3 additional communications (1 participant in the active arm 
This article is protected by copyright. All rights reserved.
15 
 
who actually received GC; 2 in the control arm who actually received GC) noted during the remainder of 
the follow-up period. The effect of actual GC on physician-patient communication throughout the follow-
up period was 5.03 (95% CI: 2.19 – 11.71) times the odds for participants who did not receive GC in PP 
analysis. The effect of receiving GC as randomized was not a significant predictor of such communication 
throughout the follow-up period in ITT analysis (OR: 1.69, 95% CI: 0.88 – 3.23, P=0.12). Neither ORs were 
significantly modified after adjusting for the total number of follow-up days.  
 
DISCUSSION 
In our study, genomic counseling of patients with chronic disease receiving potentially actionable 
complex disease and pharmacogenomics results in an academic medical setting was associated with 
increased physician-patient communication regarding testing results. The effect on increasing physician-
patient communication may rest on the ability of the genetic/genomic counselor to convey appropriate 
risks to the patient, and how their risk can be modified by individual actions (e.g. lifestyle modification) 
and through interaction with their physician team.  
A number of studies have shown that genetic counseling can improve individual basic genetic 
knowledge (17), produce more accurate risk perceptions (18) and greater perceived personal control (19-
23). We found that participants in our parent chronic disease study receiving genomic counseling had 
enhanced objective understanding of the genetic variant risk contribution to potentially actionable 
complex disease reports (24). Another study found that among women who received comprehensive 
BRCA testing ordered by their clinician, those receiving pre-test genetic counseling demonstrated 
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improved knowledge and understanding of the information received, and greater satisfaction than non-
counselees (21).  
Although it is not clear in our study who initiated conversations (patients or physicians) regarding 
genomic testing results, having access to their personalized genomic data may help activate patients to 
take independent actions to manage their disease risks (25, 26) particularly when accompanied by 
genomic counseling. Patients who are more activated are more likely to self-manage and take a more 
proactive role in their health care than patients who are less activated (27). Given that counselees were 
provided specific actions to prevent or lower disease risk, both in the counseling session and in the GC 
summary letter, and advised to speak to their study physician team regarding these recommended 
actions, it is likely these recommendations would have been fresh in the patient’s mind when they next 
saw or contacted their physician, which we found to be the case in our EMR review. Continued 
integration of genomic counselors to provide this necessary support and positive reinforcement can help 
patients discuss potentially actionable results with their physicians, who may not otherwise address 
them, and increase personal utility of the information.  
We had a 21.9% rate of physician-patient communication in the setting of genomic counseling. 
This is somewhat low but not surprising, given the physician educational intervention occurred at the 
onset of patient recruitment, was a one-time event, and the test results were forthcoming for newly 
accrued patients over the course of more than two years. Moreover, we took a passive approach in 
uploading test reports and GC summary letters into the EMR without active notification of the physician 
team as per study protocol. It is possible that physicians may not have perceived much value or benefit 
in the results. Although concern remains that personal genome results could lead to unnecessary workup 
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(28), significant post-test increases in the use of medical procedures (e.g. mammogram) are not well 
supported by the current literature (13, 21, 29), and were not found in our study (Table 2b). It is also 
likely that time was limited during visits with patients with at least one chronic disease, and therefore 
other medical concerns took precedence.  
The low rate of physician-patient result communication does suggest an opportunity for more 
active alerting of the physician team regarding genomic consultations about potentially actionable 
results, and that we should be more active in EMR documentation and routing of potentially actionable 
results and their resulting preventive recommendations. Knowing that physicians may not raise the topic 
of genomic testing results during consultations with patients, even when they are available in the EMR, 
suggests an opportunity for intervention. Genomic counselors and other health care providers trained in 
patient activation can facilitate this intervention by building patient confidence and encouraging patients 
to talk to their physicians about their results.  
The study has some limitations. First, the data were extracted from electronic chart notes. The 
content of undocumented oral communications between providers and patients, and the providers’ 
unwritten thought processes, is unknown. It is possible that additional discussions about study results 
and/or the genomic counseling intervention did take place, was not recorded, or was recorded 
incorrectly by the physician. Second, due to sample size constraints, we were unable to adjust for all 
variables in a single logistic regression model. Moreover, these analyses are likely underpowered to allow 
comment about the possible effects on physician education. Lastly, these results may not generalize 
across practice settings, or more diverse populations.  
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Our data suggest that genomic counseling appreciably affected physician-patient communication 
post-receipt of genomic risk information for multiple complex disease risks. Results of a recent 
systematic review suggest that communicating DNA based disease risk estimates has little or no effect on 
risk-reducing health behaviors (30), however, none of these prior studies facilitated participant behavior 
modification by providing genomic counseling for a range of multifactorial disease risks (relative risks 
0.08 - >6.0), and incorporating a summary plan with action steps provided to both the patient and 
provider team as was done in this study. Outcomes were primarily based on self-report of behavior 
change, and did not involve EMR review. Continued investigation of genomic counseling intervention in 
the genomic result delivery process, with the potential to motivate positive change in health-related 
measures is warranted (31).  
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Legend:  Figure 1 
*Non-compliance was when an individual had not completed the baseline surveys within a 45 day time 
limit. 
**Technical issues means the saliva DNA sample failed. 
 
 
Legend: Supplemental Figure 1:  Sample CPMC® Coronary Artery Disease Report  
Solid discs represent the participant’s relative risk, and vertical cylinders depict the range of RR values 
possible for the risk variable. On-line risk reports are organized using a tabbed approach, with separate 
tabs for disease condition information, risk results, limitations, methods, and links to request genetic 
counseling, or review educational material. To ensure readability, the CPMC report design was informed 
by multiple rounds of pilot testing conducted by allowing individuals with no scientific background to 
review report drafts and provide feedback. The CPMC chose to report relative risks to study participants 
because this approach allows  for the reporting of all  disease risk factors (genetic, family history, and 
lifestyle) using the same metric and does not require population estimates of disease incidence. The 8 
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CPMC health condition risk reports included in this study often present genetic variant risk based on a 
single SNP because of the lack of validated multigenic models with robust prediction. Risk estimates 
provided for non-genetic risk factors (family history and lifestyle or environmental factors) were derived 
or reported from valid and representative peer-reviewed publications. Non-genetic risk factors were 
included if they meet two criteria: the risk factor must be collected by the baseline required lifestyle 
questionnaire and the risk factor must be an established disease risk, included in multiple disease review 
articles and consistently associated with disease.  
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